News for 'sar'

India's 1st Covid nasal vax gets phase 2 trial nod

India's 1st Covid nasal vax gets phase 2 trial nod

Rediff.com13 Aug 2021

The first nasal vaccine against COVID-19, developed by Bharat Biotech, has received regulator's nod for conducting phase 2 clinical trials, the Department of Biotechnology said on Friday.

US says Covaxin successfully neutralises Delta variant

US says Covaxin successfully neutralises Delta variant

Rediff.com30 Jun 2021

The NIH said results of two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the United Kingdom and India, respectively.

Covid vaccine immunity durability lasts 9 months or more: Govt

Covid vaccine immunity durability lasts 9 months or more: Govt

Rediff.com30 Dec 2021

The durability of immunity post COVID-19 vaccination persists for nine months or more and a precautionary dose of vaccine which will be administered to healthcare and frontline workers and citizens above 60 years with comorbidities is to mitigate the severity of infection, hospitalisation and death, the government said on Thursday.

Mandaviya asks states to stay alert amid Covid spike

Mandaviya asks states to stay alert amid Covid spike

Rediff.com7 Apr 2023

The Centre and the states need to continue working in collaborative spirit as was done during the previous surges for COVID-19 prevention and management, Mandaviya said.

Covid-19 in Wuhan's raccoon dogs strengthens virus's natural origin theory

Covid-19 in Wuhan's raccoon dogs strengthens virus's natural origin theory

Rediff.com17 Mar 2023

A new analysis of genetic samples collected from a seafood market in central China's Wuhan city shows the presence of the SARS-CoV-2 virus in raccoon dogs sold at the venue, strengthening the case for the natural origin of the Covid-19 pandemic, according to a team of international experts.

Coronavirus may survive on phones, currency for 28 days: Study

Coronavirus may survive on phones, currency for 28 days: Study

Rediff.com12 Oct 2020

The study may also help to explain the apparent persistence and spread of SARS-CoV-2 in cool environments with high lipid or protein contamination, such as meat processing facilities and how we might better address that risk, the researchers said.

NRI from SA visiting Vadodara tests positive for Omicron BA.5

NRI from SA visiting Vadodara tests positive for Omicron BA.5

Rediff.com24 May 2022

A 29-year-old NRI who recently came to Vadodara in Gujarat from South Africa has been found infected with the BA.5 sub-variant of the highly-transmittable Omicron variant of coronavirus, a health official said on Tuesday.

AstraZeneca finds small clot risk after 1st Covid shot

AstraZeneca finds small clot risk after 1st Covid shot

Rediff.com29 Jul 2021

But no extra risk after second dose, shows study led and funded by drug maker, reports Sohini Das.

Delta plus: New Covid variant identified in India

Delta plus: New Covid variant identified in India

Rediff.com14 Jun 2021

The highly transmissible Delta variant of SARS-CoV-2 has mutated further to form the 'Delta plus' or 'AY.1' variant but there is no immediate cause for concern in India as its incidence in the country is still low, scientists in New Delhi said.

India's considerable population still vulnerable to COVID-19: ICMR

India's considerable population still vulnerable to COVID-19: ICMR

Rediff.com29 Sep 2020

One in 15 individuals aged 10 years and above were estimated to be exposed to SARS- CoV2 by August 2020, ICMR's 2nd sero-survey said.

First COVID-19 vaccine human trial finds it's safe

First COVID-19 vaccine human trial finds it's safe

Rediff.com23 May 2020

The first COVID-19 vaccine to reach phase I clinical trial is safe, well-tolerated, and capable of generating an immune response against the novel coronavirus in humans, says a new research published in The Lancet journal.

Scientists identify 70 drugs that may fight COVID-19

Scientists identify 70 drugs that may fight COVID-19

Rediff.com26 Mar 2020

The identification of host dependency factors mediating virus infection may provide key insights into effective molecular targets for developing broadly acting antiviral therapeutics against SARS-CoV-2 and other deadly coronavirus strains, according to the researchers.

India reports around 40 cases of Delta plus variant

India reports around 40 cases of Delta plus variant

Rediff.com23 Jun 2021

The Delta Plus variant have been detected sporadically in Maharashtra, Kerala and MP.

India makes RT-PCR must for passengers from 7 more nations

India makes RT-PCR must for passengers from 7 more nations

Rediff.com2 Sep 2021

These seven countries are South Africa, Bangladesh, Botswana, China, Mauritius, New Zealand and Zimbabwe.

Vaccination 3 months after recovery from Covid: Govt

Vaccination 3 months after recovery from Covid: Govt

Rediff.com19 May 2021

These decisions were taken by the ministry based on the fresh recommendations by The National Expert Group on Vaccine Administration for COVID-19 (NEGVAC) and have also been communicated to the states and union territories, an official statement said.

Covaxin 50% effective against symptomatic Covid: Lancet

Covaxin 50% effective against symptomatic Covid: Lancet

Rediff.com24 Nov 2021

Results of an interim study recently published in The Lancet showed that two doses of Covaxin, also known as BBV152, had 77.8 per cent efficacy against symptomatic disease and present no serious safety concerns.

Who's Kriti Sanon's dinner date?

Who's Kriti Sanon's dinner date?

Rediff.com15 Sep 2021

Rediff.com Contributing Photographer Pradeep Bandekar sighted these stars on Tuesday.

New COVID-19 test can give results in just 45 minutes

New COVID-19 test can give results in just 45 minutes

Rediff.com29 Apr 2020

The test named the "SARS-CoV-2 DETECTR" is easy to implement and to interpret, and requires no specialised equipment, said researchers from the University of California, San Francisco in the US.

DECODED: Why COVID-19 infects less kids than adults

DECODED: Why COVID-19 infects less kids than adults

Rediff.com22 May 2020

Lower levels of ACE2 gene expression in nasal epithelium, the first point of contact for SARS-CoV-2 and the human body, may explain why children have a lower risk of Covid-19 infection and mortality, according to a study. The researchers found that ACE2 gene expression in nasal epithelium was lowest in younger children and increased with age.

More transmissible Covid variant found, can't reduce surveillance now: WHO

More transmissible Covid variant found, can't reduce surveillance now: WHO

Rediff.com2 Apr 2022

The World Health Organisation said in its latest update that the XE recombinant (BA.1-BA.2) was first detected in the UK on January 19 and more than 600 sequences have been reported and confirmed since then.

Covishield, Covaxin effective against 'Indian strain' of Covid, study suggests

Covishield, Covaxin effective against 'Indian strain' of Covid, study suggests

Rediff.com27 Apr 2021

Anurag Agrawal, the Director of the Institute of Genomics and Integrative Biology, said the study on effectiveness of the available vaccines on the B.1.617 variant of SARS-CoV2 suggests that post vaccination, the infections are milder.

MoD signs Rs 19,600 cr deal for 17 India-made next-gen patrol, missile ships

MoD signs Rs 19,600 cr deal for 17 India-made next-gen patrol, missile ships

Rediff.com30 Mar 2023

In line with the government's vision of 'Aatmanirbhar Bharat', the ministry of defence on Thursday signed contracts with Indian shipyards for the acquisition of 11 next generation offshore patrol vessels and six next generation missile vessels at a cost of nearly Rs 19,600 crore, officials said.

Pfizer, AstraZeneca vaccines protect against Delta variant: Study

Pfizer, AstraZeneca vaccines protect against Delta variant: Study

Rediff.com15 Jun 2021

Researchers at Public Health Scotland and the University of Edinburgh, UK, found that the Pfizer-BioNTech vaccine offered better protection against the Delta variant compared to the Oxford-AstraZeneca preventive, known as Covishield in India.

New Omicron subvariants found in Maharashtra, cases up

New Omicron subvariants found in Maharashtra, cases up

Rediff.com18 Oct 2022

Maharashtra has recorded a 17.7 per cent rise in coronavirus cases compared to last week, according to a state health department bulletin.

'None of the existing vaccines can prevent emerging variants of Omicron'

'None of the existing vaccines can prevent emerging variants of Omicron'

Rediff.com25 Jan 2023

'We seem to be in a situation where we can do little, and nothing needs to be done anyway.'

Lancet Study finds Russian vaccine safe, effective

Lancet Study finds Russian vaccine safe, effective

Rediff.com4 Sep 2020

Results from early-phase non-randomised vaccine trials in a total of 76 people show that two formulations of the vaccine have a good safety profile detected over 42 days, and induce antibody responses in all participants within 21 days.

Maskless indoor interactions pose greatest Covid risk, finds study

Maskless indoor interactions pose greatest Covid risk, finds study

Rediff.com9 Jun 2021

The research, published in the Journal of Internal Medicine on Tuesday, describes how different sized respiratory droplets emitted while speaking have a range of sizes, and can carry different amounts of virus.

Children are silent spreaders of coronavirus: Study

Children are silent spreaders of coronavirus: Study

Rediff.com20 Aug 2020

The study, published in the Journal of Pediatrics, also challenges the current hypothesis that because children have lower numbers of immune receptors for SARS-CoV2, the virus that causes COVID-19, this makes them less likely to become infected or seriously ill.

Vaccine-generated antibodies no shield against Omicron, says study, booster a must

Vaccine-generated antibodies no shield against Omicron, says study, booster a must

Rediff.com2 Mar 2022

Antibodies produced by two doses of mRNA vaccines against the original and early variants of the SARS-CoV-2 virus wane substantially over time, and offer essentially no protection against Omicron, according to a study that highlights the importance of a booster dose.

Surge in Covid cases indicates endemicity: Experts

Surge in Covid cases indicates endemicity: Experts

Rediff.com7 Apr 2023

'These number surges will be the outcome of emerging virus variants, loss of vaccine- or infection-acquired protective immunity in people, and environmental factors'

No scientific evidence Mumbai case is Covid XE: Central experts

No scientific evidence Mumbai case is Covid XE: Central experts

Rediff.com6 Apr 2022

INSACOG experts are conducting genomic analysis of a coronavirus case reported as that of the highly transmissible XE variant by Mumbai civic officials, though scientific evidence so far does not indicate it to be so, official sources said on Wednesday.

British intel report says Covid may have leaked from Chinese lab

British intel report says Covid may have leaked from Chinese lab

Rediff.com31 May 2021

British intelligence agencies now believe it is 'feasible' that the COVID-19 pandemic began with a coronavirus leak from a Chinese bio laboratory, a media report said here on Sunday, prompting Vaccines Minister Nadhim Zahawi to demand that the World Health Organisation (WHO) must fully investigate the origins of the deadly virus.

No definitive conclusion on Covid origin theory: White House

No definitive conclusion on Covid origin theory: White House

Rediff.com28 Feb 2023

"The intelligence community and the rest of the government are still looking at this. There's not been a definitive conclusion, so it's difficult for me to say, nor should I feel like I should have to defend press reporting about a possible preliminary indication here," National Security Council Coordinator for Strategic Communications John Kirby told reporters at a daily White House news conference.

COVID-19 in India may have orginated from EU, Middle East: Study

COVID-19 in India may have orginated from EU, Middle East: Study

Rediff.com9 Jun 2020

The objective of the study was to determine the genetic diversity among Indian SARS-CoV-2 viral isolates in comparison to the strains that are occurring worldwide.

Scientists find different variant of Covid virus in South India

Scientists find different variant of Covid virus in South India

Rediff.com28 Jan 2021

Scientists at the CSIR-Centre for Cellular and Molecular Biology in Hyderabad have found prominently a different variant of SARS-CoV-2 in southern parts of India, a top official of the institute said on Thursday.

2021: How Covid kept the world on tenterhooks, with surprises aplenty

2021: How Covid kept the world on tenterhooks, with surprises aplenty

Rediff.com29 Dec 2021

As the Omicron strain spreads across the globe and questions on vaccine inequity dominate discussions, scientists are still scrambling to learn more about emerging variants of the deadly virus that has claimed millions of lives and crippled economies.

SARS hits grey PC market

SARS hits grey PC market

Rediff.com5 May 2003

Covaxin: No serious adverse events in phase 1 trials

Covaxin: No serious adverse events in phase 1 trials

Rediff.com16 Dec 2020

The vaccine induced robust binding and neutralising antibody responses which were comparable to those observed in the convalescent serum collected from patients who had recovered from COVID-19, according to the findings which have appeared on medRxiv, a preprint server.

Yoga, moong soup... in govt's Covid health document

Yoga, moong soup... in govt's Covid health document

Rediff.com15 Dec 2021

With the threat of COVID-19 pandemic continuing to loom over the world, the Ministry of Ayush has come out with a comprehensive document putting forth the concept of 'holistic health'.